UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Hanmi, Chong Kun Dang lead Viagra copies market
  • By So Jae-hyeon
  • Published 2018.01.22 14:44
  • Updated 2018.01.22 14:44
  • comments 0

The polarization among local drugmakers is intensifying in the erectile dysfunction drugs market.

Since patents of Pfizer’s Viagra (ingredient: sildenafil) and Lilly’s Cialis (ingredient: tadalafil) expired, scores of generic drugs appeared in the local market. Among them, Hanmi Pharmaceutical’s Palpal is leading the sildenafil market, and Chong Kun Dang’s Cendom, the tadalafil market.

However, other local drugmakers of Viagra or Cialis imitations are underperforming.

Donghwa Pharm even voluntarily canceled the approval of Hecate, a Viagra copy drug, earlier this month.

Hanmi Pharm and Chong Kung Dang’s generic drugs, however, outperformed the originals, industry data showed.

Hanmi’s Palpal sold 15.18 billion won ($14.1 million) in the first three quarters last year, dwarfing the 7.9 billion won sales of Viagra.

Chong Kun Dang’s Cendom posted 6.08 billion won in accumulated sales by the third quarter last year, closely chasing Cialis, which sold 6.49 trillion won. Hanmi’s Gugu came in the third with 3.55 billion won sales.

Except for Daewoong Pharmaceutical’s Nurigra (ingredient: sildenafil) and Taor (ingredient: tadalafil), other local generic drugs hardly achieved meaningful results. The two drugs posted 1.93 billion won, and 3.42 billion won in accumulated sales during the three quarters, respectively.

sjh@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by So Jae-hyeon
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top